This clinical trial aims to evaluate the safety and efficacy of REGEND001, an autologous bronchial basal cell therapy, for the treatment of Chronic Obstructive Pulmonary Disease (COPD). COPD is a chronic respiratory condition characterized by persistent airflow limitation and impaired lung function, leading to significant morbidity and mortality worldwide. Current treatments primarily focus on symptom management and have limited impact on disease progression or survival. This study proposes a novel approach using autologous bronchial basal cells, which have demonstrated the potential to repair damaged lung tissue and improve lung function in preclinical studies. The therapy involves the collection of bronchial basal cells via bronchial brushing, followed by their expansion and reintroduction into the patient's lungs via bronchoscopic infusion. The primary objective is to assess the improvement in lung diffusion capacity (DLCO), with secondary endpoints including changes in lung ventilation function (FEV1, FVC) and quality of life (CAT score). The study will also monitor safety, including the incidence of adverse events. Eligible participants are COPD patients aged 40-80 with moderate to severe disease. The trial includes a screening phase, cell collection, transplantation, and follow-up assessments at 4 and 24 weeks post-treatment. This study represents a promising advancement in regenerative medicine for COPD, offering a potential therapeutic option that addresses the underlying structural damage in the lungs.

开始日期2025-05-01

申办/合作机构-

NCT01060878

/ Completed临床2期

Phase II, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of PYM50028 in Subjects With Early-stage Parkinson's Disease Administered Once Daily for 28 Weeks

A study to test the therapeutic benefit of the compound PYM50028, versus placebo, in treating early-stage Parkinson's disease. Therapeutic benefit will be assessed using the Unified Parkinson's Disease Rating Scale (UPDRS). It is hypothesised that PYM50028 will be safe and well tolerated in this study and demonstrate therapeutic benefit in this patient population.

开始日期2010-11-01

申办/合作机构

Phytopharm Kleka SA

NCT00875316

/ Completed临床1期

A Randomised, Double-blind, Multiple Dose-ascending, Placebo-controlled Study in Healthy Volunteers and Parkinson's Disease Patients to Assess the Safety, Tolerability and PK of Daily Oral Administration of Cogane™ Over One Month

Phytopharm plc is developing Cogane™ which is a new medicine for the treatment of Parkinson's disease (PD). The purpose of the study is to find out if Cogane is safe and well tolerated in both healthy volunteers and Parkinson's disease patients and to determine if there is a difference in the way that the body deals with Cogane (pharmacokinetics) between these two groups.
It is expected that the study will prove that Cogane™ is safe and well tolerated and will provide us with a pharmacokinetic profile for both subject groups.

开始日期2009-04-01

申办/合作机构

Phytopharm Kleka SA

100 项与 Sarsasapogenin 相关的临床结果

登录后查看更多信息

100 项与 Sarsasapogenin 相关的转化医学

登录后查看更多信息

100 项与 Sarsasapogenin 相关的专利（医药）

登录后查看更多信息

267

项与 Sarsasapogenin 相关的文献（医药）

2026-01-01·FOOD CHEMISTRY

Quadratic polynomial prediction model-based isotope-coded equivalent reporter ion assay: A novel single-calibration LC–MS/MS strategy for sensitive quantification of steroidal sapogenin isomers in functional foods

Article

作者: Hou, Yue-Cai ; Chen, Chu ; Qing, Lin-Sen ; Huang, Xiao-Feng

Steroidal sapogenins, as characteristic components in functional foods, face LC-MS analytical challenges including difficulty separation, low ionization efficiency, and reference standards dependence. This study developed a novel quadratic polynomial prediction model (QPM) based-isotope-coded equivalent reporter ion assay (iERIA), exemplified using tigogenin and sarsasapogenin. N-Alkylpyridinium quaternization derivatization with pyridine‑d₀/d₅ impart permanent positive charges, significantly enhancing the ionization efficiency (20-fold) and chromatographic separation (12-fold) in LC-MS analysis. A common fragment ion m/z 255.4 generated by derivatization served as an equivalent reporter ion for quantification, with key MS parameters predicted via the QPM. A simultaneous quantitative method based on a single calibration curve was established and validated in complex matrices, thereby reducing reference standard costs and workload. Notably, the initial QPM for predicting the optimal combination of declustering potential and collision energy ensures the robustness of the iERIA strategy and expands its applicability to multicomponent determination using a single calibration curve.

2025-12-01·MOLECULAR DIVERSITY

Evaluation of selected indigenous spices- and herbs-derived small molecules as potential inhibitors of SREBP and its implications for breast cancer using MD simulations and MMPBSA calculations

Article

作者: Mir, Snober S ; Khan, Mohammad Kalim Ahmad ; Akhtar, Salman ; Tiwari, Urvashi

In this study, we conducted an extensive analysis of 252 bioactive compounds derived from native spices and herbs for their potential anti-breast cancer activity against sterol regulatory element-binding protein (SREBP), using in silico techniques. To evaluate the oral bioavailability, overall pharmacokinetics, and safety profiles of these compounds, we employed Lipinski's rule of five and ADME descriptors, which depicted 66 lead molecules. These molecules were then docked with the SREBP using molecular docking tools, which revealed that diosgenin and smilagenin were the most promising hits compared to the reference inhibitor betulin, with average binding affinities of - 7.42 and - 7.37 kcal/mol and - 6.27 kcal/mol, respectively. To further assess the stability of these complexes along with betulin, we conducted molecular dynamics simulations over a 100 ns simulation period. We employed various parameters, including the root-mean-square deviation, root-mean-square fluctuation, solvent-accessible surface area, free energy of solvation, and radius of gyration, followed by principal component analysis. Furthermore, we evaluated the toxicity of the selected compounds against various anticancer cell lines, as well as their metabolic activity related to CYP450 metabolism and biological activity spectrum. Based on these results, both molecules exhibited promising drug candidate potential and could be utilized for further experimental analysis to elucidate their anticancer potential.

2025-11-17·Journal of the American Nutrition Association

An Updated Insight on the Chemistry, Ethnobotany, and Health Benefits of Asparagus racemosus (Shatavari): With a Special Emphasis on Shatavarin IV

Review

作者: Das, Arpan ; Banerjee, Pradipta ; Kumar, Pawan ; Jalan, Komal ; Chakraborty, Sanjoy

Asparagus racemosus, more famous as Shatavari, is a popular medicinal plant with a broad species distribution across the Indian subcontinent as well as across the globe. The multidimensional therapeutic potential of this herb has earned it the title of "Queen of Herbs." Shatavari is rich in bioactive constituents including alkaloids, carboxylic acids, polycyclic hydrocarbons, isoflavones, flavonoids, dihydrophenanthrene derivatives, furan derivatives, essential oils, sterols, and steroidal saponin (specifically Shatavarin-I to VI), distributed throughout the rhizome as well as in other parts of the plant. These compounds are frequently used in the treatment of several medical conditions, including dysentery, diabetic retinopathy, hypertension, anxiety disorders, inflammation, tumors, mental disorders, hyperacidity, viral diseases, spasms, chronic fever, and rheumatism. In addition, Shatavari possesses antibacterial, adaptogenic, and antioxidant properties. Shatavarin IV, a sarsapogenin enriched in the roots of Shatavari, is especially beneficial for women's reproductive health and also acts as an effective stressbuster. It is used as a remedy for female infertility by boosting libido, managing sexual organ inflammation, facilitating folliculogenesis and ovulation, preparing the uterus for conception, preventing miscarriages, functioning as a postpartum tonic by enhancing lactation and restoring uterine and hormonal homeostasis. In this regard, a novel Asparagus root formulation, Shevari4T^®, has been developed, with Shatavarin IV content exceeding 7.4%, which promises to deliver the goodness of Shatavari, especially for women. This review provides a comprehensive insight into the holistic health benefits of Shatavari, with particular emphasis on Shatavarin IV.Key teaching pointsAsparagus racemosus (Shatavari) is a perennial climber medicinal plant containing multiple bioactive constituents including selected steroidal saponins, namely, Shatavarin I - VI.Shatavarin I and Shatavarin IV are the most potent glycosides found in abundance in the roots of the plant.Shatavarin IV is comprising of two molecules of rhamnose and one glucose molecule, and basically it is a glycoside of sarsasapogenin.Shatavarin IV, a steroidal saponin from Asparagus racemosus, exhibits potent pharmacological effects including antioxidant, anti-cancer, anti-inflammatory, cardioprotective, immunomodulatory, neuroprotective, antibacterial, antidiabetic and antihypertensive properties.It also augments female fertility and reproduction by facilitating folliculogenesis and ovulation, preparing the uterus for conception, preventing miscarriages, functioning as a postpartum tonic by enhancing lactation and restoring uterine and hormonal homeostasis.

项与 Sarsasapogenin 相关的新闻（医药）

2025-12-04

·EINPresswire

Raya Therapeutic unveils its Raya CARES pipeline of five clinical-stage compounds

Each new chemical entity (NCE) has substantial clinical safety data and a unique mechanism of action to treat ALS, PD, and other neurodegenerative diseases. MONTREAL, QUEBEC, CANADA, December 4, 2025 / EINPresswire.com / -- Raya Therapeutic Inc., (“Raya”) a mission-driven company focused on the treatment of amyotrophic lateral sclerosis (ALS), Parkinson's Disease (PD) and other neurodegenerative diseases, announces the unveiling of its "Raya CARES" pipeline—a portfolio of five advanced clinical-stage compounds designed with differentiated mechanisms of action to address the multifactorial biology of neurodegenerative diseases. The Raya CARES pipeline includes Cutamesine, fAsudil, Rovatirelin, Epertinib and Smilagenin. It reflects Raya’s bold commitment to advancing therapies that protect neuronal health and survival. Each compound has a distinct mechanism of action, offering complementary approaches to slowing or halting disease progression. By leveraging compounds with established human safety data (each compound has completed at least Phase 2 development involving other CNS-related indications), Raya will accelerate their development. With financing, Raya expects to advance all five compounds into large Phase 2 or Phase 3 clinical trials within 12-18 months. Pipeline Overview RT1972 (Cutamesine) – Sigma-1 receptor agonist (S1RA) • RT1972 is neuroprotective by activating the sigma-1 receptor, a key regulator of endoplasmic reticulum–mitochondrial signaling. • This drug has already completed two Phase 2 trials in other CNS indications demonstrating blood-brain barrier (BBB) penetration and safety. • Raya believes that RT1972 is the most selective and potent S1RA in development and has potential in multiple indications including Parkinson’s, Alzheimer’s, Huntington’s and in other neurodegenerative and rare diseases. RT1968 (fAsudil) – ROCK (Rho-associated kinase) inhibitor • Fasudil modulates cytoskeletal dynamics, reduces neuroinflammation, and promotes axonal regeneration, targeting both neurons and glia in ALS. • By inhibiting ROCK, fasudil decreases microgliosis, enhances oligodendrocyte survival and remyelination. • Approved in Asia for cerebral vasospasm; extensive human safety record. • Demonstrated clinical proof of concept in a large Phase 2 study in people with ALS; the study results were published in The Lancet Neurology ( LINK ) in November 2024. RT2010 (Rovatirelin) – TRH (thyrotropin-releasing hormone) analog • Rovatirelin stimulates central nervous system pathways that enhance motor neuron outgrowth and provide protection. • Raya is collaborating with Shionogi & Co., Ltd. which discovered the drug and Kissei Pharmaceutical Co., Ltd. which is developing it in a Phase 3 confirmatory study in patients with spinocerebellar ataxia (SCA) that is expected to complete enrolling in March 2027. ( NCT07040137 ). RT1978 (Epertinib) – HER2/EGFR Tyrosine Kinase Inhibitor (TKI) • Originally developed as an oncology agent that completed Phase 1/2 clinical trial development, epertinib crosses the blood–brain barrier and modulates receptor tyrosine kinase signaling. • In neurodegeneration, this mechanism may promote neuronal survival through trophic signaling and stimulating autophagy as well as reducing abnormal glial activation. • Raya is collaborating with Shionogi & Co., Ltd., which discovered and initially developed the drug. RT1999 (Smilagenin) – Neurotrophic factor modulator • Orally active, non‑peptide inducer of neurotrophic factors with blood–brain barrier penetration and extensive Phase 1/2 safety data. • Enhances production of BDNF and GDNF, supporting neuronal survival and outgrowth. • Differentiated mechanism with broad potential to treat neurodegenerative disorders. • RT1999 completed Phase 2B development in Parkinson’s Disease. While the drug missed its primary endpoints, a subsequent post-hoc analysis suggested a significant slowing of the progression of motor symptoms. "The Raya CARES pipeline represents our conviction that ALS, PD and neurodegenerative diseases demand a multipronged therapeutic strategy," said Anjan Aralihalli, President & Founder of Raya Therapeutic. "In addition to advancing each compound for development in ALS and other neurodegenerative diseases, the company has identified synergistic combinations, which it will advance as subsequent life cycle management opportunities. Combination therapies will likely be necessary to fully treat heterogenous diseases such as ALS, PD and AD.” Members of the Raya management team will attend the 36th International Symposium on ALS/MND December 4-7th in San Diego, California. Members of the management team will also be available during the JP Morgan Annual Healthcare Conference January 12 – 15th, 2026 in San Francisco, California. The J.P. Morgan Healthcare Conference is the industry's leading global investment forum, bringing together international pharma and biotech companies as well as investors across the healthcare ecosystem. For more information about Raya and its innovative pipeline, visit www.rayatherapeutic.com About Raya Raya is a mission-driven company focused on the treatment of ALS, PD and other neurodegenerative diseases, leveraging the latest techniques for the selection and development of disease-modifying therapies. The company has a robust pipeline of five distinct clinical stage compounds that each target different pathways involved in motor neuron degeneration in ALS. The compounds were in-licensed following a rigorous selection process based on biological plausibility, clinical target engagement and functional clinical effects reflective of efficacy. This diversified approach enables the development of combination therapies, which may have a significant impact on disease progression. About Shionogi & Co., Ltd. Shionogi & Co., Ltd. is a leading global research-driven pharmaceutical company dedicated to bringing benefits to patients based on its corporate philosophy of "supplying the best possible medicine to protect the health and well-being of the patients we serve." Shionogi has discovered and developed novel antibiotics, medicines for HIV and influenza and currently markets medicines for infectious diseases and central nervous system disorders. Shionogi’s global pipeline includes research programs in infectious disease, pain/CNS, metabolic disorders, rare disease, oncology and stroke. For more information, please visit https://www.shionogi.com/global/en/ . About Kissei Pharmaceutical Co., Ltd. Kissei Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company based on the management philosophy “contributing to society through high-quality, innovative pharmaceutical products” and “serving society through our employees.” As a strong R&D-oriented corporation, it concentrates on providing innovative pharmaceuticals to patients worldwide. Kissei Pharmaceutical Co., Ltd. is engaged in bringing new drugs into the world through drug discovery and licensing activities in its focus fields of rare/intractable diseases, urology, and nephrology/dialysis. For more information about Kissei Pharmaceutical Co., Ltd., please visit https://www.kissei.co.jp/e_contents/ . Anjan Aralihalli Raya Therapeutic, Inc. admin@rayatherapeutic.com Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

临床2期上市批准临床3期临床结果

2025-11-26

·干细胞与生命科学

肺部结构局部修复可见：P63+干细胞为特发性肺纤维化患者带来真实改善，肺功能提升近两成！

特发性肺纤维化（IPF）是一种不断恶化的肺部疾病。患者会感到呼吸困难、咳嗽不止，肺功能持续下降。随着肺组织逐渐“结疤”硬化，气道变窄，肺部结构受损，最终可能导致呼吸衰竭。目前常用的抗纤维化药物，如吡非尼酮和尼达尼布，虽然能稍微延缓病情发展，但无法阻止疾病恶化，更谈不上治愈，患者的生活质量依然难以改善。面对这一治疗困境，科学家将希望投向了细胞疗法。原来，我们每个人的肺里都自带“修复能手”——一种名为P63+的肺祖细胞。它们就像是肺的“维修工”，能在肺组织受损时主动进行修复，重建健康的呼吸结构。现在，医学研究者开创了新的治疗方法：从患者自身的支气管中取出少量细胞，在实验室中培育出数量充足的P63+肺祖细胞，再通过支气管镜将这些充满活力的细胞精准送回到肺部受损区域，让它们开展修复工作。值得关注的是，近期，由上海东方医院、同济干细胞中心及上海瑞金医院等多家单位共同完成的研究，首次证实了P63+肺祖细胞移植治疗特发性肺纤维化的安全性和临床疗效，为患者带来了新的希望。该研究发表在国际知名期刊《Elife》上。 1 临床试验：自体P63+肺祖细胞移植显著改善肺功能研究团队对12位晚期特发性肺纤维化（IPF）患者进行了基于自体肺祖细胞（P63+ 基底细胞）的移植治疗。医生通过支气管镜从患者肺部小气道提取少量细胞，经过体外培养扩增后再回输到患者肺内受损区域，以促进修复和再生。试验结果让人振奋——在治疗后的24周内，患者的肺功能与生活质量出现了明显的改善。从特发性肺纤维化患者中分离的P63+肺祖细胞的克隆和鉴定。具体而言： 1.肺功能改善：高剂量REGEND001治疗可以明显改善患者的肺气体交换能力（DLCO/VA），平均从72%升至84%，部分患者的用力肺活量（FVC）也略有提升，整体肺功能稳定或轻度改善。 2.运动能力提升：经过治疗，患者的6分钟步行距离平均增加58米，日常活动能力明显增强。 3.生活质量改善：治疗后，患者呼吸症状和日常活动受限减少，生活质量评分下降约6分，改善了日常生活体验。 4.肺部结构潜在修复：部分患者肺部下叶蜂窝状病变有所消退，显示干细胞可能对受损肺组织具有局部修复作用。总体评价：REGEND001干细胞疗法在IPF患者中展现出改善肺功能、增强运动能力、提升生活质量和局部修复肺组织的潜力，为患者带来新的治疗希望。干细胞治疗后不同时间点肺功能和6MWD的变化。此外，CT检查也显示，患者肺部密度逐渐下降，炎症减少，部分纤维化区域甚至出现改善迹象。这意味着，患者不仅症状好转，而且肺组织正在朝着“修复”方向变化。 REGEND001治疗前后的代表性肺部CT图像 2 安全性分析在干细胞治疗后的半年观察期内，研究人员对患者进行了系统性的安全评估。结果显示：总体安全性可控：治疗期间出现的不良反应大多数为轻微至中度，未发生与治疗相关的严重安全问题。常见暂时反应：部分患者在治疗后出现短暂发热（通常在一天内恢复）和少量痰中带血（1-3天内好转）。这些反应被认为与治疗操作相关，且均得到及时缓解。 3 重大突破：填补IPF治疗的结构修复空白与现有治疗方式不同，这项细胞疗法并不是单纯抑制炎症或纤维化，而是尝试 “修复肺结构、恢复自我再生”。研究团队表示：“我们的目标不是仅仅延缓疾病，而是帮助IPF 患者重新获得呼吸能力和生活质量。” 其他干细胞治疗方案相比，自体干细胞移植具有显著优势——免疫排异风险低，通过支气管镜提取和移植，能够避免异体干细胞和诱导多能干细胞（iPS）移植中的抗排异问题。这一治疗不仅在安全性方面表现优异，而且具有临床可及性强和成药性好的特点，未来有望广泛推广。更为重要的是，这项研究为未来干细胞药物的研发和商业化提供了宝贵的实践依据。研究团队指出，这一疗法一旦获得批准，将成为全球首个针对IPF的细胞治疗药物，为中国在再生医学领域的国际领先地位奠定坚实基础，且这一创新疗法将在全球生物医药产业中创造巨大的商业价值。 4 干细胞如何发挥作用？治疗机制简单解析自体肺祖细胞（P63+ 基底细胞）是人体肺部天然存在的组织干细胞，承担着修复受损上皮、重建肺泡屏障、改善气体交换以及抑制异常纤维化持续发展的关键任务。研究显示，这些细胞在体外扩增后仍保持强大的分化能力，移植回体内后能够参与肺组织重建，逐步恢复肺部的正常功能结构。这一机制为治疗效果的持续性提供了基础，也解释了患者在疗程结束后仍能保持肺功能改善的原因。 5 未来展望：从创新探索走向更广泛的应用此次临床试验是全国首个针对IPF的细胞治疗在人群中取得明确改善信号的研究，具有里程碑意义。基于初步疗效，研究团队已启动更大规模、随机对照的临床研究，以进一步验证安全性和疗效，并推进注册申报。未来，这一技术不仅有望为IPF患者带来突破性治疗，还可能推广到慢性阻塞性肺病（COPD）、重症肺炎后遗症及新冠康复后的肺纤维化等更广泛的肺部疾病，为更多患者带来希望。 6 结语：改变从现在开始对于长期受到呼吸困难折磨、生活质量受限的IPF患者而言，干细胞治疗带来的不仅是数字上的改善，更是一种可感知的希望——呼吸，可以重新变得轻松。随着研究不断推进，这一突破有望成为再生医学的重要里程碑，为患者开辟通向“修复与重生”的新道路，让治疗不再只是数据，而是真实可触的改善。参考资料：Zhang S, Zhou M, Shao C, Zhao Y, Liu M, Ni L, Bao Z, Zhang Q, Zhang T, Luo Q, Qu J, Xu Z, Zuo W. Autologous P63+ lung progenitor cell transplantation in idiopathic pulmonary fibrosis: a phase 1 clinical trial. Elife. 2025 Mar 4;13:RP102451. doi: 10.7554/eLife.102451. PMID: 40036154; PMCID: PMC11879106. 本文仅作健康科普，不能替代医院的检查和治疗。内容不代表任何机构立场，亦无商业推荐意图。部分内容由AI辅助生成，并经人工审核整理。 BREAK AWAY 往期推荐 01 干细胞疗法能否改善与预防心梗？全球7000+例患者3年随访数据给出答案 02 7天见证改善！301医院联合清华突破肺纤维化治疗瓶颈：干细胞雾化疗法让晚期患者重获新生 03 两周改写治疗史！《华兴时报》报道：宁医总院成功用干细胞救治一位终末期肺纤维化患者!

2025-11-13

·细胞大咖说

根据2024-2025年公开的临床研究进展，间充质干细胞在慢性呼吸系统疾病治疗中展现出显著突破

据估计，全球有5.45亿患者患有慢性阻塞性肺病，约有3.39亿患者患有哮喘。特发性肺纤维化尤其具有破坏性，患者的中位生存期仅为2-5年，而急性呼吸窘迫综合征 (ARDS) 占全球重症监护病房 (ICU) 入院患者的近10%。此外，哮喘患者的预期寿命减少约9年，在美国，COPD 相关费用每年超过500亿美元，主要是由于住院治疗。慢性呼吸系统疾病的持续性症状与生活影响除了经济和死亡率影响之外，慢性肺病的临床负担还明显体现在影响日常生活的持续性症状中。COPD、哮喘、特发性肺纤维化 (IPF) 和急性呼吸窘迫综合征 (ARDS) 患者常常会出现反复呼吸困难、慢性咳嗽咳痰和运动耐量降低，所有这些都会限制日常活动并造成心理困扰。对于哮喘患者，无法控制的呼吸困难和频繁发作往往会导致住院治疗和预期寿命缩短。现有疗法已接近生物学极限：长效支气管扩张剂仅降低26%的COPD发作风险，吸入激素减少约25%哮喘发作。新兴生物制剂虽将重度哮喘发作减少50%，但对IPF等纤维化疾病仍处研究阶段。环境暴露（如空气污染）加剧疾病早发与流行，推动技术革新需求。小分子药物再利用、CRISPR工程细胞疗法及AI药物研发平台成为优化治疗的新方向（图1）。图1：肺部疾病的当前和新兴治疗目标。最近的数据强调了在慢性呼吸系统疾病流行病学中考虑COVID-19后症状（长期 COVID）的必要性。超过1/3的COVID-19康复者出现持续三个月以上的症状，呼吸困难尤为突出，可能与肺纤维化及微血管损伤相关。长期COVID可能加重哮喘、COPD等基础病，增加管理难度。肺部康复与个性化呼吸训练可部分缓解症状，但未来需通过生物标志物识别高风险人群，并针对异质性制定个体化干预策略，以应对这一新兴健康威胁。根据2024-2025年公开的临床研究进展，间充质干细胞在慢性呼吸系统疾病治疗中展现出显著突破，尤其在慢阻肺、哮喘和肺纤维化领域取得重要成果。一、慢阻肺治疗：从机制探索到临床转化 P63阳性肺前体细胞的突破性成果：2024年2月，同济大学左为团队与钟南山院士合作的研究中，28例Ⅱ-Ⅳ期慢阻肺患者接受干细胞治疗后，肺一氧化碳弥散能力（DLCO）提升18.2%，6分钟步行距离增加30米以上，且无严重不良反应。该成果首次证实肺再生策略的临床价值，为干细胞治疗标准化提供了范例。移植自体P63阳性肺前体细胞用于慢性阻塞性肺病的治疗脂肪间充质干细胞治疗慢阻肺的III期试验启动：哈佛大学主导的RESPIRE III期多中心试验（2025年4月启动）旨在评估脂肪来源MSCs（AD-MSCs）对中度慢阻肺患者的疗效，此前I/II期数据显示其肺功能改善显著优于传统疗法。这项III期随机多中心试验旨在评估一种可能改善肺功能的替代疗法。脂肪干细胞治疗成人中度慢性阻塞性肺病：一项III期随机、多中心临床试验：RESPIRE方案慢性呼吸领域新进展：源品生物科研项目再获IND批准 2025年4月24日，国家药品监督管理局正式批准源品生物自主研发的1类生物制品——“人羊膜间充质干细胞注射液”临床试验（IND），适应症为慢性阻塞性肺疾病（COPD）。这是继该产品在中重度急性呼吸窘迫综合征领域取得临床批件后，在呼吸系统疾病治疗领域的又一里程碑突破，为国内超1亿慢阻肺患者点燃生命新希望。二、哮喘治疗：从临床试验到真实世界应用 2025年，世界干细胞杂志发表了一篇“Asthma and stem cell therapy”（干细胞治疗哮喘）的文章。正如预期的那样，MSC主要通过静脉途径给药（两项试验），而一项试验采用了鼻内给药。值得注意的是，这些研究并非旨在排除治疗的潜在不良反应，包括不受控制的MSC增殖、血管内给药后发生的血管阻塞以及注射MSC的异常分化。尽管如此，在MSC用于哮喘治疗和其他临床应用之前，必须在动物模型上优化MSC的剂量、剂型、给药途径、频率和适应症。三、肺纤维化治疗：自体干细胞的创新应用 2025年3月，以中国同济大学医学院上海市东方医院（以下简称我们）为牵头的机构进行了一项自体P63+肺祖细胞移植治疗特发性肺纤维化：1期临床试验。该临床试验结果发表在期刊杂志《Stem Cells and Regenerative Medicine》上。结果显示：肺容量（FVC）和小气道功能指标（FEF75、FEF50）显著改善；高分辨率CT显示纤维化区域缩小，肺容积增加；患者呼吸困难缓解，运动耐力提升。该研究首次验证了自体基底干细胞在重度纤维化中的修复潜力。四、间质性肺病：全球首例干细胞治疗间质性肺病临床试验成功！ 2025年5月，据合肥晚报、澎湃新闻等多家权威媒体报道，上海市第六人民医院呼吸与危重症医学科任涛教授团队，成功完成了全球首款“诱导多能干细胞（iPSC）衍生的基因修饰间充质干细胞注射液”用于治疗间质性肺病患者的临床输注。首例受试者为53岁女性。研究团队顺利完成了NCR101干细胞的静脉输注。令人欣慰的是，患者术后状态良好，未见任何不良反应。总结与展望慢性肺部疾病的治疗已从传统“一刀切”模式迈向精准化、分层的个体医疗时代。以支气管扩张剂和ICS为基础的标准化疗法仍是轻中度患者的基石，而生物标志物驱动的靶向治疗（如抗IL-5生物制剂）及联合用药策略（LABA/LAMA/ICS三联疗法）显著改善了重症患者的预后。然而，对于难治性病例或存在结构性肺损伤的患者，干细胞疗法的突破性进展为疾病修饰提供了全新可能——间充质干细胞通过抗炎、免疫调节与组织再生三重机制，或将成为逆转肺功能衰退的关键。未来，干细胞疗法与人工智能、基因编辑等技术的深度融合，有望进一步突破治疗瓶颈，实现从“控制症状”到“修复损伤”的跨越，最终重塑慢性肺病的管理范式。免责声明: 本文旨在分享科普知识，进行学术交流，或传递行业前沿进展，不作为官方立场，无任何广告目的，非进行产品贩卖，仅供读者参考。本文仅作健康科普不构成任何应用建议，不能替代医院的检查和治疗。如有相关疾病，请及时去正规医疗机构就诊，谨遵医嘱。河南省综合细胞库为储户提供相关细胞的检测、制备和存储服务。文章内容或部分素材源自网络，版权归原作者所有。若有涉及版权或其他问题，请联系我们及时删除处理。 END

临床结果临床3期细胞疗法基因疗法临床1期

100 项与 Sarsasapogenin 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Sarsasapogenin	-	DB05450

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
帕金森病（青年型、早发型）	临床2期	美国	Phytopharm Kleka SA	2010-11-01
帕金森病（青年型、早发型）	临床2期	加拿大	Phytopharm Kleka SA	2010-11-01
帕金森病（青年型、早发型）	临床2期	捷克	Phytopharm Kleka SA	2010-11-01
帕金森病（青年型、早发型）	临床2期	法国	Phytopharm Kleka SA	2010-11-01
帕金森病（青年型、早发型）	临床2期	德国	Phytopharm Kleka SA	2010-11-01
帕金森病（青年型、早发型）	临床2期	匈牙利	Phytopharm Kleka SA	2010-11-01
帕金森病（青年型、早发型）	临床2期	波兰	Phytopharm Kleka SA	2010-11-01
帕金森病（青年型、早发型）	临床2期	罗马尼亚	Phytopharm Kleka SA	2010-11-01
帕金森病（青年型、早发型）	临床2期	塞尔维亚	Phytopharm Kleka SA	2010-11-01
帕金森病（青年型、早发型）	临床2期	英国	Phytopharm Kleka SA	2010-11-01